00000000nam 2200000za 4500
0019.820810
003CaOODSP
00520221107143316
007cr |||||||||||
008161102s2016    oncd    ob   f000 0 eng d
020 |a978-0-660-05838-2
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-160/2016E-PDF
24500|aUpdate on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older |h[electronic resource] : |binterim recommendation.
2461 |iAt head of title: |aAdvisory committee statement (ACS), National Advisory Committee on Immunization (NACI)
260 |a[Ottawa] : |bPublic Health Agency of Canada, |c2016.
300 |a27 p.
500 |aIssued also in French under title: Mise à jour sur l’utilisation du vaccin conjugué 13-valent (Pneu-C-13) en plus du vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23) chez les adultes immunocompétents âgés de 65 ans et plus : recommandation provisoire.
504 |aIncludes bibliographical references.
520 |a"The objective of this Statement Update is to provide evidence and interim recommendations for the use of PNEU-C-13 in immunocompetent adults over 65 years of age and to allow informed decision making in cases when PNEU-C-13 is being considered on an individual basis for use in this age group. This statement: updates the epidemiology of pneumococcal disease in Canada for strains prevented by PNEU-C-13 to the year of the most recently available data (2013); provides an update to the review of the literature on the use of PNEU-C-13 in immunocompetent adults, which includes the recently published CAPiTA trial, as well as randomised controlled trials (RCTs) that investigate safety and immunogenicity; and provides updated, interim, recommendations for the use of PNEU-C-13 in immunocompetent individuals who are 65 years of age and over“--Introduction, p. 5.
69207|2gccst|aInfluenza
69207|2gccst|aImmunization
69207|2gccst|aSeniors
7101 |aCanada. |bNational Advisory Committee on Immunization.
7102 |aPublic Health Agency of Canada.
77508|tMise à jour sur l'utilisation du vaccin conjugué 13-valent (Pneu-C-13) en plus du vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23) chez les adultes immunocompétents âgés de 65 ans et plus |w(CaOODSP)9.820811
85640|qPDF|s1.17 MB|uhttps://publications.gc.ca/collections/collection_2016/aspc-phac/HP40-160-2016-eng.pdf
986 |a160085